Skip to main content

Table 1 Baseline characteristics of 22 HBeAg-negative CHB patients included in the study

From: HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication

Parameters All patients (N = 22) Min - Max Liver inflammation Liver fibrosis Liver inflammation or fibrosis
Significant a(n = 5) Insignificant (n = 17) p -value Significant b(n = 7) Insignificant (n = 15) p -value Significant c(n = 8) Insignificant (n = 14) p -value
Male/female, n (%) 11/11(50/50) - 1/4(5/18) 10/7(45/32) 0.127 4/3(18/14) 7/8(32/36) 0.647 4/7(18/32) 4/7(18/32) 1.000
Age, mean ± SD, years 48 ± 9 35 - 65 41.8 ± 8.3 50.1 ± 8.4 0.068 42.7 ± 8.4 50.7 ± 8.2 0.047 44.4 ± 9.1 50.4 ± 8.4 0.134
BMI, mean ± SD, kg/m2 24.54 ± 3.76 20.28 – 35.75 22.09 ± 1.51 25.26 ± 3.94 0.046 22.91 ± 1.64 25.30 ± 4.25 0.217 22.73 ± 1.61 25.57 ± 4.27 0.088
Positive family history of cirrhosis or HCC, n (%) 11/11(50) - 3/2(14/9) 8/9(36/41) 0.611 3/4(14/18) 8/7(36/32) 0.647 4/7(18/32) 4/7(18/32) 1.000
HBsAg levels, mean ± SD, log IU/mL 3.36 ± 0.55 1.57 – 4.24 3.01 ± 0.84 3.46 ± 0.42 0.225 3.39 ± 0.24 3.34 ± 0.66 0.698 3.16 ± 0.68 3.47 ± 0.46 0.275
HBV DNA levels, mean ± SD, log IU/mL 4.92 ± 1.21 3.59 – 7.56 5.45 ± 1.55 4.76 ± 1.09 0.327 5.63 ± 1.30 4.59 ± 1.04 0.053 5.40 ± 1.38 4.65 ± 1.05 0.172
TB, mean ± SD, mg/dL 0.55 ± 0.22 0.17 – 0.96 0.40 ± 0.11 0.60 ± 0.23 0.08 0.44 ± 0.20 0.61 ± 0.22 0.109 0.46 ± 0.19 0.61 ± 0.23 0.120
DB, mean ± SD, mg/dL 0.15 ± 0.07 0.03 – 0.29 0.13 ± 0.05 0.16 ± 0.07 0.288 0.14 ± 0.08 0.16 ± 0.06 0.458 0.14 ± 0.07 0.16 ± 0.07 0.580
AST, mean ± SD, mg/dL 30.3 ± 11.4 15 - 64 41.0 ± 16.8 27.1 ± 7.3 0.071 34.0 ± 15.8 28.5 ± 8.8 0.572 35.5 ± 15.2 27.3 ± 7.6 0.231
ALT, mean ± SD, mg/dL 35.4 ± 17.3 13 - 70 47.4 ± 21.8 31.9 ± 1.47 0.077 36.1 ± 20.1 35.1 ± 1.64 0.896 38.8 ± 20.4 33.5 ± 15.8 0.507
ALP, mean ± SD, mg/dL 65.2 ± 16.7 40 - 109 85.0 ± 16.7 59.4 ± 11.7 0.001 69.3 ± 16.7 63.3 ± 16.9 0.443 74.3 ± 20.9 60.0 ± 11.6 0.051
GGT, mean ± SD, mg/dL 22.3 ± 12.5 9 - 63 24.8 ± 10.6 21.5 ± 13.2 0.347 23.9 ± 10.7 21.5 ± 13.5 0.459 24.1 ± 9.9 21.2 ± 14.0 0.274
Albumin, mean ± SD, g/dL 4.47 ± 0.13 4.2 – 4.7 4.40 ± 0.16 4.49 ± 0.11 0.153 4.44 ± 0.17 4.49 ± 0.11 0.468 4.46 ± 0.17 4.48 ± 0.11 0.784
Globulin, mean ± SD, g/dL 2.96 ± 0.34 2.20 – 3.50 3.16 ± 0.27 2.91 ± 0.35 0.151 3.03 ± 0.36 2.93 ± 0.35 0.559 3.00 ± 0.34 2.94 ± 0.36 0.718
INR, mean ± SD, 0.98 ± 0.07 0.88 – 1.14 1.00 ± 0.11 0.97 ± 0.05 0.527 0.99 ± 0.07 0.97 ± 0.07 0.554 1.01 ± 0.88 0.96 ± 0.05 0.103
White blood cells, mean ± SD, /mm3 6,650 ± 1,329 4,880 – 9,100 7,168 ± 1,267 6,497 ± 1,345 0.333 6,803 ± 1,209 6,578 ± 1,416 0.721 6,773 ± 1,123 6,579 ± 1,470 0.752
Absolute neutrophil count, mean ± SD, /mm3 3,456 ± 1,132 1,819 – 6,825 4,302 ± 1,691 3,207 ± 823 0.055 3,762 ± 1,608 3,313 ± 863 0.399 3,748 ± 1,489 3,289 ± 890 0.372
Absolute lymphocyte count, mean ± SD /mm3 2,405 ± 565 1,249 – 3,583 2,222 ± 527 2,459 ± 579 0.423 2,339 ± 531 2,435 ± 595 0.719 2,345 ± 492 2,439 ± 618 0.718
Hemoglobin, mean ± SD, g/dL 13.5 ± 1.3 9.8 – 15.6 13.7 ± 1.1 13.5 ± 1.4 0.781 13.6 ± 1.0 13.5 ± 1.5 0.793 13.8 ± 1.0 13.4 ± 1.5 0.503
Platelet, mean ± SD, x103/mm3 234.5 ± 50.1 143 - 327 223.4 ± 70.2 237.8 ± 44.8 0.586 215.3 ± 55.7 243.5 ± 46.5 0.228 222.6 ± 55.6 241.2 ± 47.5 0.414
AFP, mean ± SD, ng/mL 2.71 ± 1.47 0.99 – 6.40 1.92 ± 0.62 2.95 ± 1.57 0.256 2.04 ± 0.73 3.03 ± 1.63 0.217 2.07 ± 0.68 3.08 ± 1.68 0.246
LS values, mean ± SD, kPa 7.12 ± 2.92 2.50 – 12.30 9.16 ± 3.00 6.59 ± 2.72 0.084 8.06 ± 2.56 6.77 ± 3.06 0.347 8.59 ± 2.83 6.37 ± 2.75 0.087
APRI, mean ± SD 0.35 ± 0.21 0.15 – 1.12 0.54 ± 0.37 0.30 ± 0.09 0.210 0.45 ± 0.33 0.30 ± 0.10 0.283 0.45 ± 0.31 0.30 ± 0.10 0.206
  1. Abbreviations: CHB chronic hepatitis B, BMI body mass index, TB total bilirubin, DB direct bilirubin, AST aspartate aminotransferace, ALT alanine aminotransferase, ALP alkaline phosphatase, GGT gamma glutamyltransferase, INR international normalized ratio, AFP α-fetoprotein, LS liver stiffness, APRI AST to platelet ratio index.
  2. aSignificant liver inflammation (HAI necroinflammatory activity score ≥4 or Metavir necroinflammatory activity score ≥2).
  3. bSignificant liver fibrosis (Metavir fibrosis score ≥2).
  4. cSignificant liver inflammation or fibrosis.